The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic
pulmonary fibrosis (IPF), and increased our understanding of the underlying disease …

Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal disease with a
median survival of less than three years from diagnosis. The last decade has seen an …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a prognosis
that can be worse than for many cancers. The initial stages of the condition were thought to …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and usually lethal
lung disorder of unknown etiology. The disease is characterized by alveolar epithelial cell …

Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …

During the past decade, significant advances have been made in the clinical understanding
of diffuse fibrotic lung disease. There now is a standardized diagnostic algorithm for …

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease. Until recently, the standard
therapy for this disease has been essentially supportive, with the exception of a minority of …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing
incidence; the median survival is only 35 months and as yet no therapy has been proven to …

Randomised controlled clinical trials are fundamental in medicine to develop new effective
drugs and new therapeutic regimens and are the strength of evidence-based medicine …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …